Species‐specific action of (Pro3)GIP – a full agonist at human GIP receptors, but a partial agonist and competitive antagonist at rat and mouse GIP receptors
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Background and Purpose: Specific, high potency receptor antagonists are valuable tools when evaluating animal and human physiology. Within the glucose‐dependent, insulinotropic polypeptide (GIP) system, considerable attention has been given to the presumed GIP receptor antagonist, (Pro3)GIP, and its effect in murine studies. We conducted a pharmacological analysis of this ligand including interspecies differences between the rodent and human GIP system. Experimental Approach: Transiently transfected COS‐7 cells were assessed for cAMP accumulation upon ligand stimulation and assayed in competition binding using 125 I‐human GIP. Using isolated perfused pancreata both from wild type and GIP receptor‐deficient rodents, insulin‐releasing, glucagon‐releasing and somatostatin‐releasing properties in response to species‐specific GIP and (Pro3)GIP analogues were evaluated. Key Results: Human (Pro3)GIP is a full agonist at human GIP receptors with similar efficacy (Emax) for cAMP production as human GIP, while both rat and mouse(Pro3)GIP were partial agonists on their corresponding receptors. Rodent GIPs are more potent and efficacious at their receptors than human GIP. In perfused pancreata in the presence of 7 mM glucose, both rodent (Pro3)GIP analogues induced modest insulin, glucagon and somatostatin secretion, corresponding to the partial agonist activities observed in cAMP production. Conclusions and Implications: When evaluating new compounds, it is important to consider interspecies differences both at the receptor and ligand level. Thus, in rodent models, human GIP is a comparatively weak partial agonist. Human (Pro3)GIP was not an antagonist at human GIP receptors, so there is still a need for a potent antagonist in order to elucidate the physiology of human GIP.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Biology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639 · cited 1×
“Glucose-dependent insulinotropic polypeptide (also gastric inhibitory peptide; GIP) is a hormone secreted from the K cells of the gut following a meal (Baggio and Drucker, 2007).”
BackgroundInfluentialAnimal research: Reporting in vivo experiments: The ARRIVE guidelines
Kilkenny, C., Browne, W., Cuthill, I. C., Emerson, M., & Altman, D. G. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00872.x · Cited by 3,625
Animal Research: Reporting in vivo Experiments—The ARRIVE Guidelines
Kilkenny, C., Browne, W., Cuthill, I. C., Emerson, M., & Altman, D. G. (2011) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2010.220 · Cited by 2,012
Guidelines for reporting experiments involving animals: the ARRIVE guidelines
McGrath, J., Drummond, G., McLachlan, E., Kilkenny, C., & Wainwright, C. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00873.x · Cited by 1,592
Inhibition of gastric inhibitory polypeptide signaling prevents obesity
Miyawaki, K., Yamada, Y., Ban, N., Ihara, Y., Tsukiyama, K., Zhou, H., Fujimoto, S., Oku, A., Tsuda, K., Toyokuni, S., et al. (2002) · Nature Medicine · doi:10.1038/nm727 · Cited by 963 · cited 2×
“The therapeutic potential of targeting the GIP receptor In the wake of the GIP receptor KO studies demonstrating resistance to diet-induced obesity (Miyawaki et al., 2002), many have tried to antagonize the GIP receptors as a potential target for treating obesity.”
BackgroundSelf-citationGutniak, M., Ørkov, C., Holst, J. J., Ahrén, B., & Efendić, S. (1992) · New England Journal of Medicine · doi:10.1056/nejm199205143262003 · Cited by 868 · cited 2×
“BJP British Journal ofPharmacology DOI:10.1111/bph.13323 www.brjpharmacol.org”
BackgroundInfluentialSelf-citationMiyawaki, K., Yamada, Y., Yano, H., Niwa, H., Ban, N., Ihara, Y., Kubota, A., Fujimoto, S., Kajikawa, M., Kuroe, A., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.26.14843 · Cited by 454
Glucose-Dependent Insulinotropic Polypeptide
Christensen, M., Vedtofte, L., Holst, J. J., Vilsbøll, T., & Knop, F. K. (2011) · Diabetes · doi:10.2337/db11-0979 · Cited by 353
Self-citationOn the physiology of GIP and GLP-1
Holst, J. J. (2004) · Hormone and Metabolic Research · doi:10.1055/s-2004-826158 · Cited by 189 · cited 2×
“BJP British Journal ofPharmacology DOI:10.1111/bph.13323 www.brjpharmacol.org”
BackgroundInfluentialSelf-citationAsmar, M., Simonsen, L., Madsbad, S., Stallknecht, B., Holst, J. J., & Bülow, J. (2010) · Diabetes · doi:10.2337/db10-0098 · Cited by 184 · cited 4×
“In an attempt to develop GIP receptor antagonists to be used in humans, for instance, as a putative therapeutic against obesity (Asmar et al., 2010; Ahlqvist et al., 2013), we set out to investigate functional differences between rodents and human within the GIP system in terms of ligand binding…”
BackgroundInfluentialSelf-citation
Research works printed but not linked: 50
- 10.2337/db12-0976 · DOI · Paper page
- 10.1111/bph.12445 · DOI · Paper page
- 10.1146/annurev.immunol.24.021605.090529 · DOI · Paper page
- 10.1016/j.ejphar.2014.08.019 · DOI
- 10.1016/0167-0115(83)90135-0 · DOI
- 10.1152/ajpendo.1995.269.3.E469 · DOI · Paper page
- 10.1113/jphysiol.2009.169078 · DOI · Paper page
- 10.1124/jpet.113.208637 · DOI
- 10.1073/pnas.0503942102 · DOI · Paper page
- 10.1210/en.2013-2043 · DOI
- 10.1152/ajpendo.00577.2005 · DOI · Paper page
- 10.1016/0165-6147(89)90266-6 · DOI · Paper page
- 10.1203/00006450-198004000-00008 · DOI
- Ebert R, 1979, Release of gastric inhibitory polypeptide (GIP) by intraduodenal acidification in rats and humans and abolishment of the incretin effect of acid by GIP‐antiserum in rats, Gastroenterology, 76, 515, 10.1016/S0016-5085(79)80219-X · DOI
- 10.1016/S1043-2760(01)00409-X · DOI · Paper page
- Gault Victor A, 2007, Characterisation and glucoregulatory actions of a novel acylated form of the (Pro3)GIP receptor antagonist in type 2 diabetes, Biol Chem, 388, 173
- 10.1006/bbrc.2002.6364 · DOI
- 10.1007/s00125-002-1028-x · DOI
- 10.1007/s00125-007-0710-4 · DOI
- 10.1016/S0167-0115(97)00009-8 · DOI
- 10.1016/0196-9781(96)00107-6 · doi:10.1016/0196-9781(96)00107-6
- 10.1007/s00125-008-1149-y · DOI · Paper page
- 10.1016/S0167-4838(01)00181-9 · DOI
- 10.1046/j.1365-201X.1996.37259000.x · DOI
- 10.1016/j.regpep.2006.03.006 · DOI
- 10.1007/s00125-007-0692-2 · DOI
- 10.1515/BC.2009.002 · DOI · Paper page
- 10.2337/db13-0022 · DOI · Paper page
- 10.1016/j.bbrc.2010.12.077 · DOI
- 10.1016/j.regpep.2012.08.016 · DOI
- 10.1124/pr.111.005223 · DOI · Paper page
- 10.1016/j.regpep.2011.12.006 · DOI
- 10.1016/S0140-6736(87)91194-9 · DOI · Paper page
- 10.1111/j.1476-5381.1993.tb13737.x · DOI · Paper page
- 10.1002/psc.839 · DOI
- 10.1152/ajpendo.00460.2007 · DOI · Paper page
- 10.1111/j.1463-1326.2011.01555.x · DOI · Paper page
- 10.2337/db13-1563 · DOI · Paper page
- 10.1172/JCI115012 · DOI · Paper page
- 10.1073/pnas.0706404104 · DOI · Paper page
- 10.1016/j.mce.2014.10.025 · DOI
- 10.1093/nar/gkt1143 · DOI · Paper page
- Raufman JP, 1991, Exendin‐3, a novel peptide from Heloderma horridum venom, interacts with vasoactive intestinal peptide receptors and a newly described receptor on dispersed acini from guinea pig pancreas. Description of exendin‐3(9–39) amide, a specific exendin receptor antagonist, J Biol Chem, 266, 2897, 10.1016/S0021-9258(18)49932-2 · DOI · Paper page
- 10.1074/jbc.M112.426288 · DOI · Paper page
- 10.1016/j.bmcl.2013.04.006 · doi:10.1016/j.bmcl.2013.04.006
- 10.2174/0929867321666140716093155 · doi:10.2174/0929867321666140716093155
- 10.1002/psc.1250 · DOI
- 10.1172/JCI119060 · DOI · Paper page
- 10.1016/j.bbapap.2011.04.002 · DOI
- 10.1007/s00018-010-0465-9 · DOI · Paper page
Cited by
Adriaenssens, A. E., Biggs, E. K., Darwish, T., Tadross, J., Sukthankar, T., Girish, M., Polex-Wolf, J., Lam, B. Y., Zvetkova, I., Pan, W., et al. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.07.013 · Cited by 324
Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism
Mroz, P. A., Finan, B., Gelfanov, V., Yang, B., Tschöp, M. H., DiMarchi, R. D., & Perez-Tilve, D. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2018.12.001 · Cited by 229
Adriaenssens, A. E., Svendsen, B., Lam, B. Y. H., Yeo, G. S. H., Holst, J. J., Reimann, F., & Gribble, F. M. (2016) · Diabetologia · doi:10.1007/s00125-016-4033-1 · Cited by 223
Self-citationReappraisal of GIP Pharmacology for Metabolic Diseases
Finan, B., Müller, T. D., Clemmensen, C., Perez-Tilve, D., DiMarchi, R. D., & Tschöp, M. H. (2016) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2016.03.005 · Cited by 180
Bossart, M., Wagner, M., Elvert, R., Evers, A., Hübschle, T., Kloeckener, T., Lorenz, K., Moessinger, C., Eriksson, O., Velikyan, I., et al. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2021.12.005 · Cited by 179
Targeting the Incretin/Glucagon System With Triagonists to Treat Diabetes
Capozzi, M. E., DiMarchi, R. D., Tschöp, M. H., Finan, B., & Campbell, J. E. (2018) · Endocrine Reviews · doi:10.1210/er.2018-00117 · Cited by 153
Campbell, J. E., Müller, T. D., Finan, B., DiMarchi, R. D., Tschöp, M. H., & D’Alessio, D. A. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.07.010 · Cited by 149
Recent Advances in Incretin-Based Pharmacotherapies for the Treatment of Obesity and Diabetes
Tan, Q., Akindehin, S. E., Orsso, C. E., Waldner, R. C., DiMarchi, R. D., Müller, T. D., & Haqq, A. M. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.838410 · Cited by 146
Bergmann, N. C., Lund, A., Gasbjerg, L. S., Meessen, E. C. E., Andersen, M. M., Bergmann, S., Hartmann, B., Holst, J. J., Jessen, L., Christensen, M. B., et al. (2019) · Diabetologia · doi:10.1007/s00125-018-4810-0 · Cited by 142
Self-citationTargeting the GIPR for obesity: To agonize or antagonize? Potential mechanisms
Campbell, J. E. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101139 · Cited by 133
“Species-specific sequences of GIP(3e30) retain antagonistic properties across rodent and human GIPRs; however, the most potent antagonism is seen when species specificity is matched between peptide sequences and receptors [69]. his is an open access article under the CC BY-NC-ND license (http://creativecommons.org/lic…”
BackgroundInfluentialAsmar, M., Asmar, A., Simonsen, L., Gasbjerg, L. S., Sparre-Ulrich, A. H., Rosenkilde, M. M., Hartmann, B., Dela, F., Holst, J. J., & Bülow, J. (2017) · Diabetes · doi:10.2337/db17-0480 · Cited by 132
Self-citationThe incretin co-agonist tirzepatide requires GIPR for hormone secretion from human islets
El, K., Douros, J. D., Willard, F. S., Novikoff, A., Sargsyan, A., Perez-Tilve, D., Wainscott, D. B., Yang, B., Chen, A., Wothe, D., et al. (2023) · Nature Metabolism · doi:10.1038/s42255-023-00811-0 · Cited by 118
“We first used islets isolated from mice with selective deletion of the Gipr in beta cells in combination with the GLP-1R antagonist exendin(9-39) (Ex9).”
BackgroundMethodInfluentialNørregaard, P. K., Deryabina, M. A., Tofteng Shelton, P., Fog, J. U., Daugaard, J. R., Eriksson, P., Larsen, L. F., & Jessen, L. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13034 · Cited by 116
Emerging glucagon-like peptide 1 receptor agonists for the treatment of obesity
Jepsen, M. M., & Christensen, M. B. (2021) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2021.1947240 · Cited by 96
Self-citationGlucose-dependent insulinotropic polypeptide (GIP) receptor antagonists as anti-diabetic agents
Gasbjerg, L. S., Gabe, M. B. N., Hartmann, B., Christensen, M. B., Knop, F. K., Holst, J. J., & Rosenkilde, M. M. (2018) · Peptides · doi:10.1016/j.peptides.2017.11.021 · Cited by 85
Glucose-dependent insulinotropic polypeptide (GIP) and cardiovascular disease
Heimbürger, S. M., Bergmann, N. C., Augustin, R., Gasbjerg, L. S., Christensen, M. B., & Knop, F. K. (2020) · Peptides · doi:10.1016/j.peptides.2019.170174 · Cited by 67
Self-citationDual and Triple Incretin-Based Co-agonists: Novel Therapeutics for Obesity and Diabetes
Gutgesell, R. M., Nogueiras, R., Tschöp, M. H., & Müller, T. D. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01566-x · Cited by 61
“Developing GIPR agonists has an additional challenge compared with glucagon and GLP-1, as the endogenous human and mouse GIPs differ slightly; human GIP is a poor agonist for the mouse GIPR [87, 88].”
BackgroundDiscovery of a potent GIPR peptide antagonist that is effective in rodent and human systems
Yang, B., Gelfanov, V. M., El, K., Chen, A., Rohlfs, R., DuBois, B., Kruse Hansen, A. M., Perez-Tilve, D., Knerr, P. J., D'Alessio, D., et al. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2022.101638 · Cited by 55
GIP’s involvement in the pathophysiology of type 2 diabetes
Christensen, M. B., Gasbjerg, L. S., Heimbürger, S. M., Stensen, S., Vilsbøll, T., & Knop, F. K. (2020) · Peptides · doi:10.1016/j.peptides.2019.170178 · Cited by 35
Self-citationIrwin, N., Gault, V. A., O’Harte, F. P. M., & Flatt, P. R. (2020) · Peptides · doi:10.1016/j.peptides.2019.170203 · Cited by 27
Metadata
- Authors
- Sparre‐Ulrich, A. H., Hansen, L. S., Svendsen, B., Christensen, M., Knop, F. K., Hartmann, B., Holst, J. J., & Rosenkilde, M. M.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2015-11-20
- Volume
- 173
- Issue
- 1
- Pages
- 27-38
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W2276372335
- Cited by
- 114
- References
- 12
- FWCI
- 7.57
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.